# A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus

> **NCT01648582** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 774 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Dulaglutide
- **DRUG:** Insulin glargine
- **DRUG:** Metformin
- **DRUG:** Sulfonylureas

## Key facts

- **NCT ID:** NCT01648582
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2014-08
- **Final completion:** 2014-12
- **Target enrollment:** 774 (ACTUAL)
- **Last updated:** 2019-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01648582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01648582, "A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01648582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*